Skip to main content
Onesource Specialty Pharma Limited logo

Onesource Specialty Pharma Limited — Investor Relations & Filings

Ticker · ONESOURCE ISIN · INE013P01021 LEI · 335800TP5C932B9IQT98 BSE.NS Manufacturing
Open in API
Filings indexed 156 across all filing types
Latest filing 2025-04-29 Regulatory Filings
Country IN India
Listing BSE.NS ONESOURCE

About Onesource Specialty Pharma Limited

https://www.onesourcecdmo.com/

Onesource Specialty Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) providing integrated solutions for complex pharmaceutical products. The company focuses on the development and large-scale manufacturing of specialty injectables, softgel capsules, and complex formulations. Its service portfolio encompasses the entire product lifecycle, including formulation development, clinical trial supply, and commercial-stage production. Onesource operates advanced manufacturing facilities designed to meet global regulatory standards, catering to diverse therapeutic areas. By leveraging technical expertise in sterile products and differentiated dosage forms, the organization supports global pharmaceutical partners in bringing high-entry-barrier medicines to market. The platform is built on a foundation of quality compliance and operational excellence to ensure the delivery of critical healthcare solutions.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing about an upcoming Board of Directors meeting scheduled for May 5, 2025. The purpose of the meeting includes approval of audited financial results for the quarter and year ended March 31, 2025, and taking note of the Auditors' Report. The letter also mentions the closure of the trading window in compliance with insider trading regulations until 48 hours after the dissemination of the audited results. The document does not contain the financial results or the auditors' report itself but is an announcement of the meeting where these reports will be considered. The document length is short (2221 characters) and it serves as an intimation or notification to the stock exchanges rather than the actual financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance communication rather than a full report or earnings release.
2025-04-29 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-04-29 English
General Updates
Regulatory Filings
2025-04-26 English
Shareholders meeting
Regulatory Filings
2025-04-25 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding a change in the registered office address of the company. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 30 and 51, which pertain to disclosure of material events and changes. The content is an announcement of a corporate administrative change (office relocation) rather than a financial report, management change, or other specific filings. It is not a report itself but a regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2025-04-23 English
General Updates
Regulatory Filings
2025-04-11 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.